PTAB Throws Out Janssen Patent for Prostate Cancer Drug

Drug Industry Daily
A A
The PTO’s Patent Trial and Appeal Board ruled against a Janssen patent for its prostate cancer drug Zytiga, in another setback for the company in it its efforts to keep biosimilars and generics for its drugs off the market.

To View This Article:

Login

Subscribe To Drug Industry Daily